Beigene

This is an early-stage study to check the safety and how the body processes a new oral drug called BGB-16673 in adults with chronic spontaneous urticaria (CSU), a condition causing unpredictable, itchy hives. A small group of participants will receive either the drug or a placebo…

This global study is testing whether a newer drug called zanubrutinib works better than the standard combination of bendamustine and rituximab for people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The main goal is to see which treatment …

This study is testing whether a new immunotherapy drug (BGB-A445) works better when combined with an existing one (tislelizumab) to treat advanced bladder, kidney, or skin cancers. It aims to see if the combination can shrink tumors and is safe for patients. The trial is for peop…

This study is testing whether combining an approved immunotherapy drug (tislelizumab) with new experimental drugs, with or without standard chemotherapy, can better control advanced non-small cell lung cancer. It will enroll 400 patients who have not yet received treatment for th…

This study is testing an experimental pill called BGB-11417 for people with mantle cell lymphoma, a type of blood cancer, that has come back or stopped responding to other treatments. The first part of the study aims to find a safe and effective dose. The second part will see how…

This study is testing whether a drug called BGB-290 (pamiparib) can help keep ovarian cancer from coming back in patients whose cancer returned but then responded well to platinum-based chemotherapy. It compares the drug to a placebo (inactive pill) as a long-term maintenance tre…

This study is testing whether a newer drug called zanubrutinib, when combined with rituximab, works better and is safer than the current standard chemotherapy combination for people with previously untreated mantle cell lymphoma. It's for older adults (60+) who cannot undergo ste…

This study is testing whether adding an immunotherapy drug called tislelizumab to standard chemotherapy, given both before and after surgery, works better than chemotherapy alone for people with early-stage non-small cell lung cancer. The goal is to shrink the tumor before surger…

This study is testing whether adding two experimental drugs (LBL-007 and tislelizumab) to standard maintenance therapy helps control advanced colorectal cancer better than standard therapy alone. It involves 113 patients whose cancer has spread and who responded well to initial t…

This study is testing whether an immunotherapy drug called tislelizumab, either alone or combined with other experimental drugs, can help control advanced head and neck cancer that has returned or spread. About 160 patients who have not yet received treatment for their advanced c…

This is an early-stage study to test the safety and find the right dose of a new experimental drug called BGB-15025. It is being tested alone and in combination with an existing immunotherapy drug (tislelizumab) in 157 patients with advanced solid tumors that have spread or canno…

This study is testing whether adding an experimental drug called LBL-007 to a standard immunotherapy and chemotherapy combination works better for people with advanced esophageal cancer that cannot be removed by surgery. It will involve about 118 participants who have not yet rec…

This is an early-stage study to find a safe dose of a new oral drug called BGB-11417 for adults with advanced B-cell cancers that have come back or stopped responding to standard treatments. The main goals are to check the drug's safety, see how the body processes it, and look fo…

This study is testing new, potentially safer ways to start treatment with an experimental drug called sonrotoclax for adults with chronic lymphocytic leukemia (CLL). The goal is to find the best schedule for slowly increasing the drug dose at the beginning of treatment to reduce …

This study aims to monitor the long-term safety of the cancer drug zanubrutinib in people with B-cell cancers, such as certain lymphomas and leukemias. It is open to patients who have already been taking the drug in a previous BeiGene trial and wish to continue. The main goal is …

This early-stage study is testing a new oral drug called BGB-21447 in adults with certain advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also loo…

This study is testing an experimental drug called BGB-11417 in adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to standard treatments. The trial aims to see how well the drug controls the cancer and how safe it is for pat…

This is the first study in people to test a new cancer drug called BGB-C354. Researchers want to see if it is safe, how the body processes it, and if it shows early signs of fighting cancer, both by itself and when combined with another immunotherapy drug. The study will enroll a…